GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Armephaco JSC (HSTC:AMP) » Definitions » Capex-to-Revenue

Armephaco JSC (HSTC:AMP) Capex-to-Revenue : 0.00 (As of . 20)


View and export this data going back to 2017. Start your Free Trial

What is Armephaco JSC Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Armephaco JSC's Capital Expenditure for the six months ended in . 20 was ₫0.00 Mil. Its Revenue for the six months ended in . 20 was ₫0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Armephaco JSC Capex-to-Revenue Historical Data

The historical data trend for Armephaco JSC's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Armephaco JSC Capex-to-Revenue Chart

Armephaco JSC Annual Data
Trend
Capex-to-Revenue

Armephaco JSC Semi-Annual Data
Capex-to-Revenue

Competitive Comparison of Armephaco JSC's Capex-to-Revenue

For the Medical Devices subindustry, Armephaco JSC's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Armephaco JSC's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Armephaco JSC's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Armephaco JSC's Capex-to-Revenue falls into.



Armephaco JSC Capex-to-Revenue Calculation

Armephaco JSC's Capex-to-Revenue for the fiscal year that ended in . 20 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- () /
=N/A

Armephaco JSC's Capex-to-Revenue for the quarter that ended in . 20 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- () /
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Armephaco JSC  (HSTC:AMP) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Armephaco JSC Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Armephaco JSC's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Armephaco JSC Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
No. 118, Vu Xuan Thieu Street, Phuc Loi Ward, Long Bien District, Hanoi, VNM
Armephaco JSC is engaged in the manufacturing and trading of Pharmaceuticals and medical equipment. Its products include Mist sterilization, Multi-Function Bed, High-Pressure oxygen chambers, Peripherals, Power supply units, and Other Devices.